Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Simulated model could target myeloma treatment

Ubels J et al. Nat Commun. 2018 Jul 27. doi: 10.1038/s41467-018-05348-5.

Key clinical point: A simulated treatment model estimated the benefit of using certain drugs in multiple myeloma treatment.

Major finding: Bortezomib would yield a 100% greater-than-average progression-free survival benefit in 20% of patients; lenalidomide would yield a 200% greater-than-average PFS benefit in 31% of patients.

Study details: Three randomized, phase 3 clinical trials of 910 patients with multiple myeloma were used for the simulation.

Disclosures: The Van Herk Fellowship provided support. The lenalidomide dataset was created as part of the Multiple Myeloma Research Foundation Personalized Medicine Initiative. Dr. Ubels and one coinvestigator are employees of SkylineDx; another coinvestigator served on its advisory board. The others reported having no relevant conflicts of interest.

Read the article.

Citation:

Ubels J et al. Nat Commun. 2018 Jul 27. doi: 10.1038/s41467-018-05348-5.

This Week's Must Reads

Consider bleeding disorders in heavy menstrual bleeding, O’Brien B et al. J Pediatr Adolesc Gynecol. 2018 Nov 22 . doi: 10.1016/j.jpag.2018.11.005

Lower-dose treatment could save money in aTTP, Zwicker JI et al. ASH 2018, Abstract 374

Low rates of bleeding with DOAC interruption, Douketis J et al. ASH 2018, Abstract LBA-5

Gene therapy in severe hemophilia B, Reiss UM et al. ASH 2018, Abstract 491

Luspatercept reduced transfusion burden in trial, List AF et al. ASH 2018, abstract 1

Must Reads in Multiple Myeloma

RNA editing contributes to myeloma pathogenesis, Teoh PJ et al. Blood. 2018;132(12):1304-17

Haploidentical allo-HCT possible even in relapsed myeloma, Sahebi F, et al. Biol Blood Marrow Transplant. 2018 Sep 20. pii: S1083-8791(18)30575-5.

Osteoporosis tied to mortality risk in women with multiple myeloma, Rosko AE et al. Clin Lymphoma Myeloma Leuk. 2018 Sep;18(9):597-602.e1.

Improved myeloma outcomes associated with having prescription drug coverage, Olszewski A et al. J Clin Oncol. 2018 Aug 16. doi: 10.1200/JCO.2018.77.8894

Simulated model could target myeloma treatment, Ubels J et al. Nat Commun. 2018 Jul 27. doi: 10.1038/s41467-018-05348-5.